

Errata

Zhu X, Cooper RS, Luke A, Chen G, Wu X, Kan D, Chakravarti A, Weder A: A genome-wide scan for obesity in African-Americans. *Diabetes* 51:541–544, 2002

The authors of the above-listed article would like to make the following corrections: In Table 2, the “*P* value” column heading should be changed to “LOD score.” In Table 3, markers “D3S2394” and “D3S2419” should appear as “D3S2398” and “D3S2418,” respectively.

Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR: The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. *Diabetes* 51:2826–2832, 2002

Nathan L. Alderson’s name was incorrectly listed in the above article in the September issue of *Diabetes*. The correct author list is shown above.

Iglesias MA, Ye J-M, Frangioudakis G, Saha AK, Tomas E, Ruderman NB, Cooney GJ, Kraegen EW: AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. *Diabetes* 51:2886–2894, 2002

On page 2891 of the above-listed article, seven lines from the bottom of the first complete paragraph, reference citations 17 and 18 should be 29 and 30, respectively. In addition, due to duplicate citations in the reference list of refs. 2 (repeated as 29) and 11 (repeated as 19), all references subsequent to ref. 18 are mismatched in the text. Thus, the correct listing of refs. 19–50 is shown below.

REFERENCES

19. Kraegen EW, James DE, Storlien LH, Burleigh KM, Chisholm DJ: In vivo insulin resistance in individual peripheral tissues of the high fat fed rat: assessment by euglycaemic clamp plus deoxyglucose administration. *Diabetologia* 29:192–198, 1986
20. Kraegen EW, James DE, Bennett SP, Chisholm DJ: In vivo insulin sensitivity in the rat determined by euglycemic clamp. *Am J Physiol* 245:E1–E7, 1983
21. Kraegen EW, James DE, Jenkins AB, Chisholm DJ: Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. *Am J Physiol* 248:E353–E362, 1985
22. Ellis BA, Poynten A, Lowy AJ, Furler SM, Chisholm DJ, Kraegen EW, Cooney GJ: Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. *Am J Physiol* 279:E554–E560, 2000
23. Chan TM, Exton JH: A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. *Anal Biochem* 71:96–105, 1976
24. McGarry JD, Stark MJ, Foster DW: Hepatic malonyl-CoA levels of fed, fasted and diabetic rats as measured using a simple radioisotopic assay. *J Biol Chem* 253:8291–8293, 1978
25. Saha AK, Kurowski TG, Colca JR, Ruderman NB: Lipid abnormalities in tissues of the KK^Y mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. *Am J Physiol* 267:E95–E101, 1994
26. Vavvas D, Apazidis A, Saha AK, Gamble J, Patel A, Kemp BE, Witters LA, Ruderman NB: Contraction-induced changes in acetyl-CoA carboxylase and 5′-AMP-activated kinase in skeletal muscle. *J Biol Chem* 272:13255–13261, 1997
27. Tomas E, Sevilla L, Palacin M, Zorzano A: The insulin-sensitive GLUT4 storage compartment is a postendocytic and heterogeneous population recruited by acute exercise. *Biochem Biophys Res Commun* 284:490–495, 2001
28. Carlson CL, Winder WW: Liver AMP-activated protein kinase and acetyl-CoA carboxylase during and after exercise. *J Appl Physiol* 86:669–674, 1999
29. Winder WW, Holmes BF, Rubink DS, Jensen EB, Chen M, Holloszy JO: Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. *J Appl Physiol* 88:2219–2226, 2000
30. Buhl ES, Jessen N, Schmitz O, Pedersen SB, Pedersen O, Geoffrey D, Holman, Lund S: Chronic treatment with 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. *Diabetes* 50:12–17, 2001
31. Delp MD, Duan C: Composition and size of type I, IIA, IID/X, and IIB fibers and citrate synthase activity of rat muscle. *J Appl Physiol* 80:261–270, 1996
32. James DE, Jenkins AB, Kraegen EW: Heterogeneity of insulin action in individual muscles in vivo: euglycemic clamp studies in rats. *Am J Physiol* 248:E567–E574, 1985
33. Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, Jenkins AB, Storlien LH: Skeletal muscle triglyceride levels are inversely related to insulin action. *Diabetes* 46:983–988, 1997
34. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. *Am J Med* 107:450–455, 1999
35. Virkamaki A, Korshennikova E, Seppala-Lindroos A, Vehkavaara S, Goto T, Halavaara J, Hakkinen AM, Yki-Jarvinen H: Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. *Diabetes* 50:2337–2343, 2001
36. Kraegen EW, Cooney GJ, Ye JM, Thompson AL, Furler SM: The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes and obesity. *Exp Clin Endocrinol Diabetes* 109:S189–S201, 2001
37. Thompson AL, Cooney GJ: Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance. *Diabetes* 49:1761–1765, 2000
38. Faergeman NJ, Knudsen J: Role of long-chain fatty acyl-CoA esters in the regulation of metabolism and in cell signalling. *Biochem J* 323:1–12, 1997
39. Itani SI, Zhou Q, Pories WJ, MacDonald KG, Dohm GL: Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. *Diabetes* 49:1353–1358, 2000
40. Ruderman NB, Saha AK, Vavvas D, Witters LA: Malonyl-CoA, fuel sensing, and insulin resistance. *Am J Physiol* 276:E1–E18, 1999
41. Brown NF, Hill JK, Esser V, Kirkland JL, Corkey BE, Foster DW, McGarry JD: Mouse white adipocytes and 3T3-L1 cells display an anomalous pattern of carnitine palmitoyltransferase (CPT) I isoform expression during differentiation: inter-tissue and inter-species expression of CPT I and CPT II enzymes. *Biochem J* 327:225–231, 1997
42. Holmes BF, Kurth-Kraczek EJ, Winder WW: Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. *J Appl Physiol* 87:1990–1995, 1999
43. Fisher JS, Gao J, Han DH, Holloszy JO, Nolte LA: Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. *Am J Physiol* 282:E18–E23, 2002
44. Richter EA, Garetto LP, Goodman MN, Ruderman NB: Muscle glucose metabolism following exercise in the rat: increased sensitivity to insulin. *J Clin Invest* 69:785–793, 1982

45. Garetto LP, Richter EA, Goodman MN, Ruderman NB: Enhanced muscle glucose metabolism after exercise in the rat: the two phases. *Am J Physiol* 246:E471–E475, 1984
46. Derave W, Ai H, Ihlemann J, Witters LA, Kristiansen S, Richter EA, Ploug T: Dissociation of AMP-activated protein kinase activation and glucose transport in contracting slow-twitch muscle. *Diabetes* 49:1281–1287, 2000
47. Aschenbach WG, Fujii N, Howlett KF, Sakamoto K, Goodyear LJ: Acute AICAR treatment elicits fiber-type specific responses in glycogen metabolism in vivo (Abstract). *Diabetes* 50 (Suppl.1):A60, 2001
48. Winder WW: Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. *J Appl Physiol* 91:1017–1028, 2001
49. Lochhead PA, Salt IP, Walker KS, Hardie DG, Sutherland C: 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. *Diabetes* 49:896–903, 2000
50. Fiedler M, Zierath JR, Selén G, Wallberg-Henriksson H, Liang Y, Sakariassen KS: 5-aminoimidazole-4-carboxy-amide-1- β -D-ribofuranoside treatment ameliorates hyperglycaemia and hyperinsulinaemia but not dyslipidaemia in KKAY-CETP mice. *Diabetologia* 44:2180–2186, 2001

Tan C, Tuch BE, Tu J, Brown SA: Role of NADH shuttles in glucose-induced insulin secretion from fetal β -cells. *Diabetes* 51:2989–2996, 2002

On page 2995, the words “and is restored to normal” were inadvertently omitted from the last sentence of the first complete paragraph. The correct sentence is shown below.

This is consistent with reports that mGPDH activity is decreased in islets of humans (18) and animals with type 2 diabetes (17,33) and is restored to normal when blood glucose is normalized (34).